In the BioHarmony Drug Report Database
Lofexidine
Lucemyra (lofexidine) is a small molecule pharmaceutical. Lofexidine was first approved as Lucemyra on 2018-05-16. It is used to treat substance withdrawal syndrome in the USA. It is known to target alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, and alpha-2C adrenergic receptor.
Trade Name
|
Lucemyra |
|---|---|
Common Name
|
lofexidine |
ChEMBL ID
|
CHEMBL17860 |
Indication
|
substance withdrawal syndrome |
Drug Class
|
Image (chem structure or protein)